Abstract
We would like to thank Schlachetzki et al for their comments and interest in our article about the administration of tirofiban, which may cause a higher incidence of fatal intracerebral hemorrhage and poor outcome in patients who have received endovascular stroke therapy.1,2 We fully agree with the highlighted limitations, which were already mentioned in our article (eg, higher rate of stenting in the tirofiban group). Of course, the main limitation is the nonrandomized study design, which gives imbalances between the groups. A further limitation of our study is that tirofiban was not only administered after stent implantation, but also in patients in whom endothelial damage was suspected (for example, …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
